Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

Editas Medicine. 2016. Editas Medicine announces closing of initial public offering and full exercise of option to purchase additional shares. Available at: http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-newsArticle&ID=2136486 (accessed March 4, 2016).

Editas Medicine. 2016. Prospectus, Form 424B1, filed February 3, 2016. Available at: http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-sec&secCat01.1_rs=21&secCat01.1_rc=20 (accessed March 4, 2016).

Seiffert

. 2016. What recent gene therapy offerings tell us about today's Editas IPO. Boston Business Journal, February 3. Available at: www.bizjournals.com/boston/blog/bioflash/2016/02/what-recent-gene-therapy-offerings-tell-us-about.html (accessed March 4, 2016).

AveXis. 2016. AveXis announces pricing of initial public offering. Available at: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2137418 (accessed March 4, 2016).

AveXis. 2016. Prospectus filed February 11. Available at: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwNzMzNzA3JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3#cq70204_use_of_proceeds (accessed March 4, 2016).

Hethcock

. 2016. AveXis gene therapy firm files for $115 million IPO. Dallas Business Journal, January 19. Available at: www.bizjournals.com/dallas/news/2016/01/19/avexis-gene-therapy-firm-in-dallas-files-for-115m.html (accessed March 4, 2016).

Avalanche Biotechnologies and Annapurna Therapeutics. 2016. Avalanche Biotechnologies and Annapurna Therapeutics announce proposed merger. Available at: http://investors.avalanchebiotech.com/phoenix.zhtml?c=253634&p=irol-newsArticle&ID=2133923 (accessed March 3, 2016).

PTC Therapeutics. 2016. PTC Therapeutics reports fourth quarter and full year 2015 financial results and provides corporate update. Available at: http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=957888 (accessed March 5, 2016).

BioMarin Pharmaceutical. 2016. FDA issues complete response letter for Kyndrisa^™ (drisapersen) for DMD amenable to exon 51 skipping. Available at: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=950309 (accessed March 5, 2016).

10.

Carroll

. 2016. PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators' doors to ataluren. FierceBiotech, February 29. Available at: www.fiercebiotech.com/story/ptc-no-evidence-duchenne-md-efficacy-fda-barred-regulators-doors-ataluren/2016-02-29 (accessed March 5, 2016).

11.

Sarepta Therapeutics. 2016. Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen. Available at: http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2136367 (accessed March 5, 2016).

12.

GlaxoSmithKline and Adaptimmune. 2016. GSK and Adaptimmune expand strategic immunotherapy collaboration. Available at: www.gsk.com/en-gb/media/press-releases/2016/gsk-and-adaptimmune-expand-strategic-immunotherapy-collaboration/ (accessed March 3, 2016).